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Risk factors for intensive care unit admission and
mortality in hospitalized COVID-19 patients
Ahmed Ayaz1,*, Ainan Arshad2,*, Hajra Malik1, Haris Ali1, Erfan Hussain3, Bushra Jamil4
1

Medical College, Departments of 2Internal Medicine, 3Pulmonary and Critical Care, and 4Infectious Diseases, Aga Khan University, Karachi, Pakistan

Background: This study investigated the clinical features and outcome of hospitalized coronavirus disease 2019 (COVID-19) patients admitted to our quaternary care hospital.
Methods: In this retrospective cohort study, we included all adult patients with COVID-19
infection admitted to a quaternary care hospital in Pakistan from March 1 to April 15, 2020.
The extracted variables included demographics, comorbidities, presenting symptoms, laboratory tests and radiological findings during admission. Outcome measures included in-hospital
mortality and length of stay.
Results: Sixty-six COVID-19 patients were hospitalized during the study period. Sixty-one percent were male and 39% female; mean age was 50.6 ± 19.1 years. Fever and cough were the
most common presenting symptoms. Serial chest X-rays showed bilateral pulmonary opacities
in 33 (50%) patients. The overall mortality was 14% and mean length of stay was 8.4 ± 8.9
days. Ten patients (15%) required intensive care unit (ICU) care during admission, of which six
(9%) were intubated. Age ≥ 60 years, diabetes, ischemic heart disease, ICU admission, neutrophil to lymphocyte ratio ≥ 3.3, and international normalized ratio ≥ 1.2 were associated with
increased risk of mortality.
Conclusions: We found a mortality rate of 14% in hospitalized COVID-19 patients. COVID-19
cases are still increasing exponentially around the world and may overwhelm healthcare systems in many countries soon. Our findings can be used for early identification of patients
who may require intensive care and aggressive management in order to improve outcomes.
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INTRODUCTION
Despite technological advancements in the field of medicine, humans remain vulnerable to
emerging infectious threats. A viral pneumonia of unknown etiology that first surfaced in
Wuhan, China has since spread rapidly across the globe. Various mitigation and suppression
strategies for disease control have yielded mixed results. Severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has established itself as a highly adaptable pathogen that is easily transmissible, causing asymptomatic infections in a large majority of people and inflicting
great damage when it encounters a vulnerable host [1,2].
As of November 12, 2020, it had killed more than 1.3 million people and led to nearly 52 million confirmed cases around the world [3]. Early studies revealed that the most frequent presenting symptoms of this disease to be fever, cough, fatigue, sore throat and dyspnea [4]. El-
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derly patients and those with a higher comorbidity burden
have a worse prognosis when compared to their younger and
healthier counterparts. The former are also at a higher risk of
developing acute respiratory distress syndrome (ARDS) and
cytokine storm, to devastating effect [5]. To validate these
findings, we investigated the clinical features and outcomes of
hospitalized coronavirus disease 2019 (COVID-19) patients
admitted to our quaternary care center.

MATERIALS AND METHODS
Study Design/Data Source
In this retrospective cohort study, we included all adult patients with laboratory-confirmed COVID-19 infection admitted to Aga Khan University Hospital from March 1 to April 15,
2020. The study was approved by the Institutional Review
Board of Aga Khan University (IRB No. 2020-3686-10185).
Owing to the retrospective design, the requirement for informed consent was waived.
Patients presenting to COVID-19 screening clinics were initially evaluated by physicians and those who met the World
Health Organization (WHO) criteria for suspected infection
were admitted into the COVID-19 isolation ward for further
evaluation and baseline workup. Specimens collected via nasopharyngeal swab were tested for COVID-19 using an reverse
transcription polymerase chain reaction (RT-PCR) assay (Roche,
Basel, Switzerland). These patients were managed according
to disease severity per WHO guidelines. Patients classified as
having severe and critical disease were managed in the intensive care unit (ICU). Patients were discharged after two negative PCRs at least 24 hours apart.
We identified these cases using the presence of an International Classification of Diseases (ICD-9) code for SARS-associated Coronavirus (079.82). COVID-19 PCR results of these
patients were then determined by the research team using an
electronic medical record system. A confirmed case of COVID-19 was defined by a positive result on RT-PCR assay of a
specimen collected via nasopharyngeal swab. Only laboratory-confirmed cases were included and analyzed. Patients who
remained in the hospital at the time of data censoring on April
15, 2020 were not included as their outcomes were not
known.

Data Collection
Data was collected from the hospital’s electronic medical record system by the research team members according to a
preapproved proforma. The data was deidentified before anal250 https://www.accjournal.org

KEY MESSAGES
■ Overall mortality in hospitalized coronavirus disease
2019 (COVID-19) patients was 14% and mean length of
stay was 8.4 ± 8.9 days.
■ Ten patients (15%) required intensive care unit (ICU) care
during admission, of which six (9%) were intubated.
■A
 ge ≥ 60 years, diabetes, ischemic heart disease, ICU
admission, neutrophil to lymphocyte ratio ≥ 3.3 and international normalized ratio ≥1.2 were associated with
increased risk of mortality.
■O
 ur findings can be used for early identification of patients who may require intensive care and aggressive
management in order to improve outcomes.
ysis. The extracted variables included demographics, comorbid conditions, presenting symptoms, laboratory investigations and radiological findings during the admission. Outcome
measures included in-hospital mortality and length of stay.

Statistical Analysis
IBM SPSS ver. 22.0 (IBM Corp., Armonk, NY) was used for
data analysis. We used Student t-test or Wilcoxon rank-sum
test for continuous variables, and chi-square test or Fisher exact test for categorical variables, based on cell counts to determine associations between those who died and those who
survived. We calculated odds ratios for each factor separately
after adjusting for potential confounders such as age, sex and
comorbid conditions. A P-value ≤ 0.05 was considered significant.

RESULTS
Sixty-six laboratory-confirmed cases of COVID-19 were admitted to Aga Khan University Hospital during the study period. There were more males (61%) in our cohort; the mean age
was 50.6 ± 19.1 years. Nine patients (14%) presented asymptomatically, while fever (60%) was the most common presenting symptom. Mean time from symptom onset to presentation
at the hospital and subsequent hospitalization was 3.8 ± 2.3
days. Twelve patients (18%) had a recent travel history with
the United Arab Emirates being the most frequent country of
stay. Tables 1 and 2 detail the baseline characteristics and
hospitalization factors of patients who died compared with
those who survived.
Serial chest radiography (CXR) was obtained in all patients
and 33 (50%) showed bilateral pulmonary opacities at some
point during their stay. The mean length of hospital stay was
Acute and Critical Care 2020 November 35(4):249-254
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Table 1. Demographic and clinical characteristics of COVID-19 patients
Characteristics

Overall (n=66)

Expired (n=9)

Survived (n=57)

P-value

Mean age (yr)

50.6 ± 19.1

74.8 ± 9.4

46.8 ± 17.2

<0.001

Male

40 (61)

9 (100)

31 (54)

Female

26 (39)

0

26 (46)

Diabetes

25 (38)

8 (89)

17 (30)

0.001

Hypertension

30 (46)

8 (89)

22 (39)

0.009

Ischemic heart disease

10 (15)

6 (67)

4 (7)

Chronic kidney Disease

3 (5)

3 (33)

0

0.002

Asthma

2 (3)

0

2 (4)

0.999

Malignancy

4 (6)

2 (22)

2 (4)

0.087

9 (14)

0

9 (16)

0.341

Fever

40 (60)

4 (44)

36 (63)

0.259

Cough

34 (51)

4 (44)

30 (53)

0.492

Dyspnea

15 (23)

7 (78)

8 (14)

<0.001

Sore throat

9 (14)

0

9 (16)

0.332

Headache

5 (8)

0

5 (14)

0.999

Nausea/vomiting

4 (6)

0

4 (7)

0.999

10 (15)

4 (44)

6 (11)

0.024

6 (9)

3 (33)

3 (5)

0.029

Length of stay

8.3 ± 6.7

8.7 ± 6.0

6.5 ± 7.4

0.270

Mean time from symptom onset to hospitalization (day)

3.8 ± 2.3

3.3 ± 2.7

3.9 ± 2.3

0.954

-

9.1 ± 9.4

-

Hydroxychloroquine-azithromycin combination

12 (18)

4 (44)

8 (14)

0.055

Hydroxychloroquine alone

23 (35)

6 (67)

17 (30)

0.055

Azithromycin alone

16 (24)

5 (56)

11 (19)

0.032

5 (8)

4 (44)

1 (2)

0.001

18 (27)

6 (67)

12 (21)

0.010

4 (6)

1 (11)

3 (5)

0.452

Sex

0.009

Comorbid condition

<0.001

Presenting symptom
Asymptomatic

Hospitalization factor
ICU admission
Mechanical ventilation

Mean time from symptom onset to death (day)

-

Treatment

Tocilizumab
Broad spectrum antibiotics
Systemic glucocorticoids
Values are presented as mean ± standard deviation or number (%).
COVID-19: coronavirus disease 2019; ICU: intensive care unit.

8.4 ± 8.9 days. Twelve (18%) received a hydroxychloroquineazithromycin combination, 23 patients (35%) received hydroxychloroquine alone and 16 (24%) received azithromycin alone.
Hydroxychloroquine was discontinued in one patient due to
QT prolongation. Furthermore, five patients (8%) received tocilizumab. Eighteen patients (27%) were started on broad spectrum antibiotics on suspicion of a secondary bacterial infection. Only three of the subsequent blood cultures were posiAcute and Critical Care 2020 November 35(4):249-254

tive, showing Pseudomonas aeruginosa, Klebsiella pneumoniae
and methicillin-resistant Staphylococcus aureus, respectively.
Non-ST elevation myocardial infarction during the hospital
stay was observed in 5% of cases. Ten patients (15%) developed
moderate-to-severe ARDS and were managed in the ICU with
prone positioning and noninvasive ventilation. Six of these
patients (9%) required mechanical ventilation due to respiratory failure. There were three (50%) and one (25%) deaths in
https://www.accjournal.org
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Table 2. Laboratory tests and radiological findings of COVID-19
patients
Overall
(n=66)

Characteristics

Expired
(n=9)

Survived
(n=57)

Table 3. Adjusted odds of ICU admission in COVID-19 (n=66)
Crude Adjusted
odds odds ratio

Characteristics
P-value

Chest X-ray finding

0.002

5.3

4.9

1.1–21.6

0.029

Hypertension

6.3

6.2

1.2–31.4

0.020

5.7

5.5

1.2–25.3

0.037

14.2

12.3

1.4–101.2

0.006

5.6

5.2

1.2–23.1

0.029

33 (50)

0

33 (58)

Ischemic heart disease

Bilateral infiltrates

33 (50)

9 (100)

24 (42)

Bilateral infiltrates on chest
radiography

13.3 ± 2.1

12.9 ± 2.4

13.5 ± 2.1

0.578

WBC count (×10E9/L) 9.0 ± 7.1

11.6 ± 4.1

8.6 ± 7.4

0.246

Neutrophil to lymphocyte ratio

4.0 ± 3.8

9.5 ± 4.9

3.1 ± 2.8

<0.001

Procalcitonin (ng/ml)

1.1 ± 2.1

0.3 ± 0.1

1.5 ± 2.6

0.221

Hb (g/dl)

86.8 ± 86.7 83.6 ± 80.8 88.1 ± 91.1

CRP (mg/L)

Serum lactate (mmol/L) 1.9 ± 1.5

2.7 ± 2.3

0.912

1.5 ± 0.8

0.184

P-value

Diabetes

Normal
Laboratory test

95% CI

Neutrophil to lymphocyte
ratio ≥3.3

ICU: intensive care unit; COVID-19: coronavirus disease 2019; CI: confidence interval.

Table 4. Adjusted odds of mortality in COVID-19 (n=66)
Characteristics

Crude
odds

Adjusted
odds

95% CI

P-value

0.652

Age ≥60 years

22.4

20.5

2.4–177.3

0.001

803 ± 738

0.919

Diabetes

19.2

18.8

2.2–162.4

0.001

2.4 ± 1.5

0.9 ± 0.8

<0.001

Hypertension

12.9

12.7

1.5–108.8

0.009

0.8 ± 0.4

0.7 ± 0.5

0.820

Ischemic heart disease

28.6

26.5

4.7–147.8

0.001

101 ± 485

444 ± 1,209

35 ± 18

0.019

ICU admission

15.1

14.6

2.6–80.4

0.001

ALT (IU/L)

100 ± 461

421 ± 1,148

38 ± 29

0.021

Mechanical ventilation

12.4

9.0

1.4–54.9

0.029

PT (sec)

11.3 ± 1.2

12.8 ± 1.9

10.9 ± 0.8

<0.001

1.5

1.4

1.1–1.7

0.002

PTT (sec)

26.8 ± 7.4

29.3 ± 4.9

25.6 ± 7.7

0.289

Bilateral infiltrates on
chest radiography

1.1 ± 0.1

1.2 ± 0.2

1.0 ± 0.1

<0.001

Neutrophil to lymphocyte ratio ≥3.3

1.7

1.6

1.1–2.2

0.001

INR ≥1.2

8.5

8.3

1.6–41.2

0.010

LDH (I.U/L)

803 ± 1,364 569 ± 197

949 ± 1762

0.646

D-dimer (mg/L FEU)

2.9 ± 5.2

3.7 ± 7.1

2.4 ± 3.6

Ferritin (ng/ml)

791 ± 769

760 ± 934

Creatinine (mg/dl)

1.1 ± 1.2

Total bilirubin (mg/dl)

0.7 ± 0.4

AST (IU/L)

INR

Values are presented as number (%) or mean ± standard deviation.
COVID-19: coronavirus disease 2019; Hb: hemoglobin; WBC: white
blood cells; CRP: C-reactive protein; LDH: lactate dehydrogenase; AST:
aspartate aminotransferase; ALT: alanine transaminase; PT: prothrombin
time; PTT: partial thromboplastin time; INR: international normalized
ratio.
66 COVID-19
patients

10 (15%) Patients
admitted to ICU

4 (40%)
Patients
expired

6 (60%)
Patients
survived

56 (85%) Patients
admitted to ward

5 (9%)
Patients
expired

51 (91%)
Patients
survived

Figure 1. Outcomes of hospitalized coronavirus disease 2019 (COVID-19) patients (n=66). ICU: intensive care unit.

the mechanical ventilation and noninvasive ventilation groups,
respectively (Figure 1). The overall mortality rate was 14%. Mortality in the ICU was 40% compared to 9% in the general ward.
252 https://www.accjournal.org

COVID-19: coronavirus disease 2019; CI: confidence interval; ICU: intensive care unit; INR, international normalized ratio.

The five ward patients that expired had issued do-not-resuscitate orders.
Factors associated with ICU admission included diabetes,
hypertension, ischemic heart disease, neutrophil to lymphocyte ratio ≥ 3.3 and international normalized ratio (INR) ≥ 1.2.
The odds of ICU admission are presented in Table 3. Factors
associated with mortality included age ≥ 60 years, diabetes,
hypertension, ischemic heart disease, ICU admission, neutrophil to lymphocyte ratio ≥ 3.3 and INR ≥ 1.2. The odds of mortality are presented in Table 4.

DISCUSSION
In this study, we present clinical characteristics and outcomes
of 66 COVID-19 patients admitted to a quaternary care center
in Karachi, Pakistan. Younger patients and females of all age
groups were less likely to be hospitalized compared to males
Acute and Critical Care 2020 November 35(4):249-254
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of older age. This is consistent with results from recent studies
conducted in China, Italy and the United States [6-8]. However, whether these differences are due to less exposure to the
virus or an innate biological resistance to it remains unclear.
A history of recent travel from the Middle East and the United Kingdom was observed in 19% of our cases. Fever and cough
were the most common initial symptoms on admission while
11% of patients presented asymptomatically within another
medical or surgical condition and were diagnosed on screening. Only 60% of patients with COVID-19 presented with fever,
which is much lower than that in Wuhan (98%) and Shanghai
(84%) [9,10]. While body temperature remains the main monitoring tool for surveillance of cases, many afebrile patients in
our population would have been missed. Our results corroborate findings from a study conducted by Mao et al. [11], which
assessed 50,000 patients presenting to 25 fever clinics in China, and concluded that fever was not a reliable indicator for
COVID-19 screening.
Chest computed tomography (CT) reveals typical radiogra
phic features, namely ground-glass opacities and multifocal
patchy consolidations, in almost all COVID-19 patients, even
when COVID-19 PCR is negative [12-14]. Unfortunately, due
to limited resources and financial constraints, chest CT was
not performed in any of our patients during the initial weeks
of the pandemic; CXR was used as a cheaper and more readily
available alternative. Bilateral infiltrates were seen in exactly
half of the patients and these findings were also significantly
associated with a poor prognosis when compared with those
who had normal CXR findings. The utilization of CXR instead
of CT in COVID-19 patients’ needs to be studied further, especially in resource-restricted settings. Similarly, lung ultrasound
is another cost-effective radiological modality that has proven
to be extremely useful in triaging patients with suspected COVID-19. It can rapidly detect extensive pulmonary involvement
in COVID-19 patients, allowing for timely referral to the ICU if
needed [15].
Several therapeutic agents have been evaluated for the treatment of COVID-19, but none have been established to be efficacious. The usefulness of hydroxychloroquine in COVID-19
remains inconclusive. Tang et al. [16] performed a randomized control trial assessing 150 patients admitted at 16 hospitals in China and reported no significant improvement in clinical outcomes. Adverse events were more common in hydroxychloroquine recipients than in non-recipients. Our study showed
similar results. The use of hydroxychloroquine appeared to be
associated with poor outcomes. Remdesivir, an inhibitor of
the viral RNA-dependent-RNA polymerase has been identiAcute and Critical Care 2020 November 35(4):249-254

fied as a promising therapeutic candidate for COVID-19 because of its ability to inhibit SARS-CoV-2 in vitro. Beigel et al.
[17] performed a randomized controlled trial that enrolled
1,063 patients and concluded that Remdesivir was superior to
placebo in shortening the time to recovery in hospitalized
COVID-19 patients with evidence of respiratory tract infection.
We found a higher mortality rate (14%) in our patients compared to the rates that have been reported in other countries
[8,10,18,19]. Many patients who were asymptomatic or had
mild symptoms did not present to COVID-19 screening clinics, and hence were not tested. Therefore, realistically, the mortality rate can be presumed to be significantly lower. ICU admission and the need for mechanical ventilation in our cohort
were reflective of disease severity; mortality was higher among
patients who required invasive ventilation. The mortality rate
of 40% in ICU patients is slightly lower than the rate reported
among critically ill patients in the United States and China [6,
20,21]. As confirmed by recent studies worldwide, male sex,
older age and comorbid conditions were significant also risk
factors for ICU admission and mortality in our study [22,23].
Our study has potential limitations. Since this is a singlecenter study conducted over a limited time period, the sample
size was relatively small. Furthermore, the confidence interval
for many factors was wide, likely due to the small number of
patients in the study. Our results revealed an extremely high
mortality rate in COVID-19 patients with moderate-to-severe
disease who required hospitalization. COVID-19 cases are still
increasing exponentially around the globe and may overwhelm
healthcare systems in many countries. Our findings can be
used for early identification of patients who may require intensive care and aggressive management in order to improve
outcomes.
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